667463-95-8

Usage

Uses

Used in Pharmaceutical Industry:
1-METHYL-BIO is used as a therapeutic agent for targeting GSK3 and cyclin-dependent kinases, which play crucial roles in various cellular processes and diseases. Its inhibitory action on these kinases makes it a potential candidate for the treatment of disorders associated with their dysregulation, such as cancer and neurodegenerative diseases.
Used in Cancer Research:
1-METHYL-BIO is used as a research tool for studying the role of GSK3 and cyclin-dependent kinases in cancer development and progression. Its potent inhibitory effects on these kinases can help researchers understand their involvement in tumor growth, survival, and resistance to therapies, ultimately leading to the development of novel cancer treatments.
Used in Neurodegenerative Disease Research:
1-METHYL-BIO is used as a research compound for investigating the role of GSK3 in neurodegenerative diseases, such as Alzheimer's and Parkinson's. Its inhibitory action on GSK3 can provide insights into the potential therapeutic benefits of targeting this kinase in the context of neuroprotection and disease modification.
Used in Drug Development:
1-METHYL-BIO is used as a lead compound in the development of new drugs targeting GSK3 and cyclin-dependent kinases. Its potent inhibitory properties and selectivity make it a valuable starting point for designing and optimizing novel therapeutic agents with improved efficacy, safety, and pharmacokinetic profiles.

Upstream product

• 591-19-5 m-Bromoaniline 
• 667463-64-1 6-bromo-N-methylisatin 
• 6326-79-0 6-bromoisatin 
• 667463-98-1 1-Methyl-6-bromoindirubin 
• 65971-74-6 N-(3-bromophenyl)-2-(hydroxyimino)ethanamide 

Relevant academic research and scientific papers

INDIRUBIN-TYPE COMPOUNDS, COMPOSITIONS, AND METHODS FOR THEIR USE

Compounds and compositions including 6-bromo-indirubin, 5-amino-indirubin and N-methyl-indirubins and related indirubin derivatives are provided that are useful as selective modulators of glycogen synthase kinase-3, cyclin-dependent protein kinases or aryl hydrocarbon receptors. Methods of inhibiting or modulating cell growth or cell cycling are provided using the compounds of the invention. In other aspects, compounds and methods for the treatment of protozoan-mediated diseases, Alzheimer's disease and diabetes are provided.

Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases

Pharmacological inhibitors of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinases have a promising potential for applications against several neurodegenerative diseases such as Alzheimer's disease. Indirubins, a family of bis-indoles isolated from various natural sources, are potent inhibitors of several kinases, including GSK-3. Using the cocrystal structures of various indirubins with GSK-3β, CDK2 and CDK5/p25, we have modeled the binding of indirubins within the ATP-binding pocket of these kinases. This modeling approach provided some insight into the molecular basis of indirubins' action and selectivity and allowed us to forecast some improvements of this family of bis-indoles as kinase inhibitors. Predicted molecules, including 6-substituted and 5,6-disubstituted indirubins, were synthesized and evaluated as CDK and GSK-3 inhibitors. Control, kinase-inactive indirubins were obtained by introduction of a methyl substitution on N1.